Design Highlights
- Medicare Part B drug spending has increased nearly 9% annually since 2009, reaching $47 billion in 2022.
- A 53% rise in cost per claim from 2008 to 2016 significantly contributed to spending growth, despite decreased utilization.
- Specialty drugs, while comprising 25% of claims, consumed 88% of Part B spending in 2016, highlighting skewed cost distribution.
- Beneficiaries face substantial out-of-pocket costs, with 25% incurring at least $1,000 in cost sharing for Part B drugs.
- The Budget Reconciliation Act of 2022 offered limited relief, leaving Congress urgently seeking comprehensive solutions to address unsustainable costs.
Medicare Part B drug costs are skyrocketing—like, hold onto your wallets high. Spending on these drugs has ballooned at nearly 9% a year since 2009. That’s not just a little bump; it’s like a full-blown financial avalanche. By 2021, Medicare fee-for-service Part B drug spending hit a staggering $33 billion. Fast forward to 2022, and both Medicare and its beneficiaries coughed up nearly $47 billion for Part B-covered drugs and biologics. The numbers are dizzying, and yet, they keep climbing.
Medicare Part B drug costs are soaring—nearly 9% annually, hitting $47 billion in 2022. The financial avalanche is just getting started.
What’s driving this madness? It’s not because more folks are using these drugs. Oh no, utilization actually dropped by 12% from 2008 to 2016. Instead, it’s all about the cost per claim. That rose a jaw-dropping 53% during the same period. Specialty drugs, while only 25% of claims in 2016, gobbled up a whopping 88% of the spending. It seems like the only thing growing faster than these prices is the number of people questioning their sanity as they fill their prescriptions. Moreover, Part B drugs had the fastest rate of spending growth among drugs in the Medicare program over past decades.
And here’s the kicker: traditional Medicare requires a 20% coinsurance for Part B drugs. No cap on out-of-pocket expenses. So, guess what? Among the 4.1 million traditional Medicare beneficiaries using these drugs back in 2019, a quarter faced at least $1,000 in cost sharing. That’s not a small chunk of change. Nearly 20% had to deal with at least $2,000. It’s like a cruel game where the house always wins.
Medicare Advantage isn’t much better either. Enrollees often face similar cost-sharing woes, with out-of-pocket limits that can stretch into the thousands. In 2022, common limits were $7,550 in-network and $11,300 combined for out-of-network. Good luck steering through that minefield. The broader insurance market reflects similar pressures, as employer-sponsored health coverage costs are projected to exceed $16,000 per employee annually in 2025.
As for how these drugs get priced, most are paid at average sales price plus 6% under the law. That might sound reasonable until you realize the context. The Budget Reconciliation Act of 2022 may have added a glimmer of hope for some, but the response feels like a Band-Aid on a gaping wound. In 2015, Part B total drug spending rose to $24.6 billion, highlighting the ongoing financial strain.
In short, Medicare Part B drug costs are on an unsustainable trajectory. Beneficiaries are left holding the bag, while Congress scrambles to figure out how to keep people from drowning in costs. It’s a mess, and as the numbers keep climbing, one can’t help but wonder: when will it all come crashing down?
